Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Reports More Clinical Data on BTK-inhibitor Brukinsa

publication date: Dec 9, 2019

BeiGene of Beijing released positive clinical results from three trials of its BTK inhibitor Brukinsa™ at this year's American Society of Hematology Meeting. Two oral presentations showed Brukinsa was well-tolerated and produced a 93% overall response in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. A poster presentation reported a combination of Brukinsa and BeiGene's anti-PD-1 antibody tislelizumab demonstrated preliminary signs of efficacy in patients with previously treated B-cell malignancies. In November, Brukinsa received its first marketing approval as a treatment for mantle cell lymphoma in the US. More details....

Stock Symbols: (NSDQ: BGNE; HKEX: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.